Teva Pharmaceutical Industries Ltd, ADR (TEVA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Yitzhak Peterburg
Employees:
42,535
5 BAZEL ST, P O B 3190, PETACH TIKVA, ISRAEL 49131
9729267267

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Data derived from most recent annual or quarterly report
Market Cap 9.342 Billion Shares Outstanding1.103 Billion Avg 30-day Volume 9.864 Million
P/E Ratio21.1873 Dividend Yield0.0 EPS0.19
Price to Revenue0.5564 Debt to Equity2.0494 EBITDA1.988 Billion
Price to Book Value0.8596 Operating Margin10.807400000000001 Enterprise Value30.679 Billion
Current Ratio1.14 EPS Growth1.104 Quick Ratio0.607
1 Yr BETA 0.936 52-week High/Low 11.55 / 7.23 Profit Margin2.8719
Operating Cash Flow Growth-34.375 Altman Z-Score0.2539 Free Cash Flow to Firm 3.677 Billion
View SEC Filings from TEVA instead.

View recent insider trading info

Funds Holding TEVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TEVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

130 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FRIDRIKSDOTTIR HAFRUN EXECUTIVE VP, GLOBAL R&D

  • Officer
1,387 2022-05-17 5

SABAG MARK EVP, INTERNATIONAL MARKETS

  • Officer
552,788 2022-03-04 3

STARK DAVID MATTHEW EXEC. VP CHIEF LEGAL OFFICER

  • Officer
383,202 2022-03-04 3

SCHULTZ KARE PRESIDENT AND CEO

  • Officer
  • Director
3,456,597 2022-03-04 4

DETHLEFS SVEN EVP, NORTH AMERICA COMMERCIAL

  • Officer
728,120 2022-03-04 3

DANIELL RICHARD EXEC. VP, EUROPEAN COMMERCIAL

  • Officer
369,819 2022-03-04 3

DRAPE ERIC EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
448,024 2022-03-04 3

KALIF ELIYAHU SHARON EVP, CHIEF FINANCIAL OFFICER

  • Officer
263,088 2022-03-04 3

SHANI ELI EVP,GLOBAL MARKETING&PORTFOLIO

  • Officer
131,715 2022-03-04 3

INBAR GALIA SEE "REMARKS"

  • Officer
112,926 2022-03-04 3

WEISS AMIR CHIEF ACCOUNTING OFFICER

  • Officer
101,360 2022-03-04 3

ZAKS TAL ZVI

  • Director
17 2021-12-31 3

WEIL ANDREW CHIEF ACCOUNTING OFFICER

  • Officer
29,673 2021-11-02 1

LIEBERMAN GERALD M

  • Director
14,479 2021-06-14 3

BARER SOL J

  • Director
25,791 2021-06-14 3

MIGNONE ROBERTO

  • Director
14,479 2021-06-14 3

CRANE ROSEMARY A

  • Director
14,479 2021-06-14 3

VERGIS JANET S.

  • Director
14,479 2021-06-14 2

NISEN PERRY

  • Director
14,479 2021-06-14 3

ELSTEIN AMIR

  • Director
14,479 2021-06-14 3

HALFON JEAN MICHEL

  • Director
14,479 2021-06-14 3

PERES NECHEMIA JACOB

  • Director
14,479 2021-06-14 3

SATCHI-FAINARO RONIT

  • Director
51,359 2021-06-14 3

HUSSAIN ABBAS

  • Director
14,479 2021-06-14 1

NAZZI GIANFRANCO EVP, INTERNATIONAL MARKETS

  • Officer
25,870 2021-03-04 0

O'GRADY BRENDAN P. EVP, NORTH AMERICA COMMERCIAL

  • Officer
188,299 2021-03-04 0

GRIFFIN DEBORAH A CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-03-17 0

MCCLELLAN MICHAEL JAMES EVP, CHIEF FINANCIAL OFFICER

  • Officer
15,898 2019-11-05 0

GOLDBERG MURRAY A

  • Director
0 2019-06-11 0

DE NOTARISTEFANI CARLO EXECUTIVE VP GLOBAL OPERATIONS

  • Officer
33,589 2019-05-18 0

CODNER IRIS BECK EVP GLOBAL BRAND&COMMUNICATION

  • Officer
0 2019-03-04 0

SUESSKIND DAN S

  • Director
318,836 2018-01-19 0

GREENE-SULZBERGER GABRIELLE

  • Director
0 2018-01-01 0

MAOR GALIA

  • Director
0 2018-01-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FRIDRIKSDOTTIR HAFRUN - Officer EXECUTIVE VP, GLOBAL R&D

2022-05-19 07:31:18 -0400 2022-05-17 S 130,000 $8.22 d 1,387 direct 1.9254 1.9254 2 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 22:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 21:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 21:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 20:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 20:15:05 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 19:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 19:15:04 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 18:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 18:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 17:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 17:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 16:45:04 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 16:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 15:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 15:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 14:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 14:15:04 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 13:45:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 13:15:03 UTC 0.4119 0.4081 0
TEVA PHARMACEUTICAL-SP ADR TEVA 2022-05-20 12:45:03 UTC 0.4119 0.4081 0

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
UBS RELATIONSHIP FUNDS- UBS U.S. EQUITY ALPHA RELATIONSHIP FUND TEVA -145400.0 shares, $-1792782.0 2020-06-30 N-PORT
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund TEVA -14705.0 shares, $-169695.7 2021-03-31 N-PORT
Legg Mason Global Asset Management Trust- Franklin Global Market Neutral Fund TEVA -46800.0 shares, $-439452.0 2022-03-31 N-PORT

Elevate your investments